期刊文献+

51例获得性血栓性血小板减少性紫癜患者的临床研究 被引量:9

The clinical studies of 51 patients with thrombotic thrombocytopenic purpura
原文传递
导出
摘要 目的分析获得性血栓性血小板减少性紫癜(TTP)患者的临床特征、治疗策略及转归。方法回顾性分析51例获得性TTP患者的临床资料。采用GraphPadPrism5软件对数据资料进行分析。结果51例患者中男17例、女34例,中位年龄41(13-90)岁;仅18例(35.29%)表现为典型五联征,以血小板减少(100.00%)、微血管病性溶血性贫血(92.16%)、神经精神症状(88.24%)较为多见,而发热(72.55%)及肾脏损害(70.59%)相对少见。37例患者进行血浆血管性血友病因子裂解蛋白酶(ADAMTSl3)活性检查,其中31例(83.78%)ADAMTSl3活性〈5%。36例(70.59%)患者治疗有效,血浆置换和血浆输注有效率为72.3%。15例(29.41%)患者死亡,8例(22.22%)复发。死亡患者发病年龄、治疗前总胆红素水平均高于治疗有效患者[(50.1±18.9)岁对(37.5±14.5)岁,P=0.008;(63.7±39.7)μmol/L对(43.3±23.5)μmol/L,P=0.036],而体温、白细胞数、血红蛋白、血小板计数、血肌酐及LDH差异均无统计学意义(P〉0.05)。结论TTP患者的诊断依赖临床资料综合分析。血浆ADAMTSl3活性检测有助于TTP的临床诊断。血浆置换疗效较好,联合糖皮质激素、免疫抑制剂、利妥昔单抗可进一步降低病死率及复发率。高龄及总胆红素增高患者预后欠佳。 Objective To comprehensively analyze the clinical characteristics, treatment strategies and outcome of patients with thrombotic thrombocytopenic purpura (TTP). Methods A retrospective survey of 51 TTP patients confirmed in our database. Relevant statistical analyzes were performed by GraphPad Prism 5 software. Results 51 cases of patients with acquired TTP were identified as idiopathic TTE In our study, only 18 cases (35.29%) had typical pentalogy of TTP, where thrombocytopenia ( 100.00% ), microangiopathic hemolytic anemia (92.16%) and neurologic abnormalities (88.24%) were more common than fever (72.55%) and renal abnormalities (70.59%). Plasma ADAMTS13 activity was detected in 37 patients with TTP with ADAMTS 13 deficiency confirmed in 31 patients (83.78%). Plasma exchange with response of 72.3% was still the preferred strategy in TTP with individuation. Among 36 survival TTP patients, 8 patients (22.22%) relapsed. 15 patients (29.41%) died in our study. The mean ages of resonders and deaths were of (37.5±14.5) and (50.1±18.9) respectively; whereas total bilirubin level of resonders and deaths were of (43.3±23.5) μmol/L and (63.7±39.7) μmol/L respectively, the differences were statistically significant. Conversely, body temperature, WBC, HGB, PLT, serum creatinine and LDH showed no significant differences (P 〉 0.05). Conclusion The diagnosis of TTP was based on comprehensive analysis of clinical manifestations. Plasma ADAMTS 13 activity test had a higher clinical practical value. The therapeutic alliance with corticosteroids, immunosuppressive agents and Rituximab significantly improved its outcome. The age and high total bilirubin level at onset were associated with lesssensitive to plasmapheresis and poor prognosis.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2014年第2期147-151,共5页 Chinese Journal of Hematology
关键词 紫癜 血栓性血小板减少性 血管性血友病因子裂解蛋白酶 血浆置换 治疗结 Purpura thrombotic thrombocytopenic ADAMTS13 Plasma exchange Outcome
  • 相关文献

参考文献25

  • 1George JN. Clincal practice.Thrombotic thrombocytopenic purpura[J].{H}New England Journal of Medicine,2006,(18):1927-1935.
  • 2Sadler JE. Von Willebrand factor,ADAMTS13,and thrombotic thrombocytopenic purpura[J].{H}Blood,2008,(1):11-18.
  • 3Porta C,Caporali R,Montecucco C. Autoimmunity in thrombotic thrombocytopenic purpura[J].{H}Seminars in Thrombosis and Hemostasis,2005,(6):633-640.
  • 4Kwaan HC. Thrombotic thrombocytopenic purpura:a diagnostic and therapeutic challenge[J].{H}Seminars in Thrombosis and Hemostasis,2005,(6):615-624.
  • 5Zheng X,Chung D,Takayama TK. Structure of von Willebrand factor-cleaving protease (ADAMTS13),a metalloprotease involved in thrombotic thrombocytopenic purpura[J].{H}Journal of Biological Chemistry,2001,(44):41059-41063.
  • 6Sadler JE,Moake JL,Miyata T. Recent advances in thrombotic thrombocytopenic purpura[J].Hematology Am Soc Hematol Educ Program,2004.407-423.
  • 7无,阮长耿,余自强.血栓性血小板减少性紫癜诊断与治疗中国专家共识(2012年版)[J].中华血液学杂志,2012,33(11):983-984. 被引量:125
  • 8秦燕,苏健,黄石兵,刘红.ADAMTS13活性及抑制物测定在ITTP诊断中的价值[J].南通大学学报(医学版),2009,29(6):437-438. 被引量:6
  • 9Zhan H,Streiff MB,King KE. Thrombotic thromboeytopenic purpura at the Johns Hopkins Hospital from 1992 to 2008:clinical outcomes and risk factors for relapse[J].{H}TRANSFUSION,2010,(4):868-874.
  • 10Gurkan E,Baslamisli F,Guvenc B. Thrombotic thrombocytopenic purpura in southern Turkey:a single-center experience of 29 cases[J].{H}Clinical Laboratory Hematology,2005,(2):121-125.

二级参考文献25

共引文献134

同被引文献57

  • 1高维强,苏健,邢秀萍,王京华,白霞,王兆钺,阮长耿.von Willebrand因子裂解酶活性水平的检测及其临床应用[J].中国实验血液学杂志,2004,12(6):726-729. 被引量:9
  • 2李洪霞,赵玉凤,刘灿霞,李德鹏,鹿群先,黄一虹.血浆置换治疗血栓性血小板减少性紫癜的护理体会[J].护理实践与研究,2007,4(11):30-31. 被引量:2
  • 3M, Marinescu A, Remy H.A peculiar mechanism of hydrocephalus: the "water-hammering" effect[J].Neuro- Chirurgie,2011,44(2): 117-20.
  • 4C, I iguez J A, Mauri P.Mandibular neuropathy due to infiltration of the Gasser ganglion[J].Revista de neurolog ia,2010,25( 143): 1092-1094.
  • 5Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura[J]. Blood, 2011, 118(7):1746-1753.
  • 6Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura[J]. Blood, 2008, 112(1):11-18.
  • 7Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group[J]. Ann Intern Med, 1995, 122(8): 569-572.
  • 8Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features[J]. Br J Haematol, 2008, 142(5):819-826.
  • 9Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 andmanti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission[J]. Haematologica, 2008, 93(2): 232-239.
  • 10Kremer Hovinga JA, L?mmle B. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura[J]. Hematology Am Soc Hematol Educ Program, 2012, 2012:610-616.

引证文献9

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部